Guilin Sanjin Pharmaceutical (002275.SZ) achieved a net profit of 391 million yuan in 2023, an increase of 18.58% year-on-year.

Guilin Sanjin Pharmaceutical (002275.SZ) released its preliminary report of 2023 annual performance, during the reporting period, the company achieved operating income of 2.172 billion yuan, an increase of 10.82% compared to the same period of the previous year; net profit attributable to the shareholders of the listed company was 391 million yuan, an increase of 18.58% compared to the same period of the previous year. Main reasons are as follows: 1. During the reporting period, the company continued to promote marketing innovation, seized market opportunities, increased sales efforts, and achieved stable growth in performance; 2. The company actively carried out lean management and energy-saving projects to improve management efficiency and effectively control costs; 3. The management expenses confirmed by the first phase of the employee stock ownership plan in the current period decreased compared to the same period of last year; 4. The company optimized the bio-pharmaceutical sector, achieving a certain degree of loss reduction.